Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.
Kevin Sean Murnane, Shane Alan Perrine, Brendan James Finton, Matthew Peter Galloway, Leonard Lee Howell, William Edward Fantegrossi
Psychopharmacology April 2012 DOI: 10.1007/s00213-011-2504-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational animal study Peer reviewed |
|---|---|
| Population | Mice exposed to MDMA, methamphetamine, or parachloroamphetamine |
| Interventions | MDMA Methamphetamine Parachloroamphetamine |
| Measures | Passive avoidance (PA) behavior, ex vivo high-pressure liquid chromatography |
| Key findings | Methamphetamine and parachloroamphetamine impaired passive avoidance performance and significantly depleted dopamine, serotonin, and their metabolites in several brain regions, while MDMA did neither. Anterior striatal dopamine concentration was the strongest predictor of passive avoidance performance, with a further significant contribution from cingulate 5-hydroxyindoleacetic acid. The authors suggest these impairments may be attributable to specific neurochemical depletions. |
Abstract
Considerable evidence indicates that amphetamine derivatives can deplete brain monoaminergic neurotransmitters. However, the behavioral and cognitive consequences of neurochemical depletions induced by amphetamines are not well established. In this study, mice were exposed to dosing regimens of 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (METH), or parachloroamphetamine (PCA) known to deplete the monoamine neurotransmitters dopamine and serotonin, and the effects of these dosing regimens on learning and memory were assessed. In the same animals, we determined deficits in learning and memory via passive avoidance (PA) behavior and changes in tissue content of monoamine neurotransmitters and their primary metabolites in the striatum, frontal cortex, cingulate, hippocampus, and amygdala via ex vivo high-pressure liquid chromatography. Exposure to METH and PCA impaired PA performance and resulted in significant depletions of dopamine, serotonin, and their metabolites in several brain regions. Multiple linear regression analysis revealed that the tissue concentration of dopamine in the anterior striatum was the strongest predictor of PA performance, with an additional significant contribution by the tissue concentration of the serotonin metabolite 5-hydroxyindoleacetic acid in the cingulate. In contrast to the effects of METH and PCA, exposure to MDMA did not deplete anterior striatal dopamine levels or cingulate levels of 5-hydroxyindoleacetic acid, and it did not impair PA performance. These studies demonstrate that certain amphetamines impair PA performance in mice and that these impairments may be attributable to specific neurochemical depletions.
Citations in the library
Cited by 6
- Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder Frontiers in Psychiatry March 14, 2023
- The Acute Toxic and Neurotoxic Effects of 3,4-methylenedioxymethamphetamine are More Pronounced in Adolescent than Adult Mice Behavioural Brain Research December 3, 2019
- Of mice and men on MDMA: a translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Brain Research November 14, 2019
- Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice Psychopharmacology July 15, 2019
- Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose. Pharmacological Reviews July 1, 2019
and 1 more in the library
Cites 10
- Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings The Lancet October 1, 1998
- Memory impairment in abstinent MDMA ("Ecstasy") users Neurology December 1, 1998
- Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user Neurology July 25, 2000
- 3,4‐methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein Synapse July 14, 2004
- Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use Psychological Medicine January 28, 2004
and 5 more in the library